Status:
COMPLETED
An Investigation of the Mechanism of Action of Seretide in Chronic Obstructive Pulmonary Disease
Lead Sponsor:
University of Southampton
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
35-80 years
Phase:
PHASE4
Brief Summary
This study is investigating the possible mechanisms of action of an inhaled treatment (Seretide), currently used worldwide in millions of patients with COPD (Chronic Obstructive Pulmonary Disease) and...
Detailed Description
We aim to recruit equal numbers of healthy smokers, mild, moderate and severe COPD patients (12 patients to be recruited from each group). These patients will never have been prescribed the components...
Eligibility Criteria
Inclusion
- \>35yrs.
- \>10 Pack Years COPD as defined as an FEV1\<70% and an FEV1/FVC ratio of \<70%
Exclusion
- Asthma
- Lung cancer
- Bronchiectasis
Key Trial Info
Start Date :
February 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2012
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00974805
Start Date
February 1 2010
End Date
February 1 2012
Last Update
December 8 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Southampton General Hospital
Southampton, Hampshire, United Kingdom, SO16 6YD